 |
Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results
Oct 31, 2011
|
40.5 KB |
|
| |
Completes Acquisition of Astex Therapeutics Limited
Dacogen Royalty Revenue Increases 26% from Prior Year
Ends Quarter with $128 Million in Cash & Marketable Securities
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), formerly Supe...
|
|
Astex Pharmaceuticals to Present a Novel Targeted Approach to the Treatment of HCV at the AASLD Meeting
Oct 31, 2011
|
14.2 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company
dedicated to the discovery, development and commercialization of novel
therapeutics, announced that it will present data on its novel,
first-in-class direct acting antiviral agents (DAA) against Hepatitis C
...
|
|
Evidence of AT13387 Activity in Gastrointestinal Stromal Tumor Models Presented at ECCO
Sep 27, 2011
|
15.6 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company
dedicated to the discovery and development of novel cancer therapies,
announced that preclinical data demonstrating that AT13387, a novel
non-ansamycin Heat Shock Protein 90 (HSP90) inhibitor, is active in in
...
|
|
SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website
Sep 12, 2011
|
15.9 KB |
|
| |
DUBLIN, Calif.--(BUSINESS WIRE)--
SuperGen, Inc. (NASDAQ:ASTX) announced that it has officially begun
operating under the name Astex Pharmaceuticals, Inc. Concurrent with
this new name, and effective at the start of trading today, September
12, 2011, the ticker symbol for the Company's common stock listed on
...
|
|
SuperGen Reports 2011 Second Quarter Financial Results
Aug 3, 2011
|
32.8 KB |
|
| |
DUBLIN, Calif., Aug 03, 2011 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ: SUPG) today reported financial results for the
second quarter ended June 30, 2011. The Company reported net income for
the 2011 second quarter of $903,000, or $0.01 per basic and diluted
share, compared with $961,000, or $0.02 per basic and dilu...
|
|
FDA Accepts DACOGEN(R) (Decitabine) sNDA Submission in Acute Myeloid Leukemia
Jul 13, 2011
|
10.7 KB |
|
| |
DUBLIN, Calif., Jul 13, 2011 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, announced that
Eisai Inc. today released information that the U.S. Food and Drug
Administration (FDA) has accepted for review its supplemental N...
|
|
SuperGen President & CEO Elected to BIO Board of Directors
Jun 28, 2011
|
9.7 KB |
|
| |
DUBLIN, Calif., Jun 28, 2011 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, announced that its
chairman, president and chief executive officer, James S.J. Manuso,
Ph.D., has been elected to the Full Board of Directors of...
|
|
SuperGen Stockholders Approve Stock Issuance In Connection with the Proposed Acquisition of Astex Therapeutics Limited
Jun 16, 2011
|
10.9 KB |
|
| |
DUBLIN, Calif., Jun 16, 2011 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, announced that
stockholders have approved the issuance of shares to be issued in
connection with the proposed acquisition of Astex Therapeutics ...
|
|
SuperGen, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Jun 6, 2011
|
6.0 KB |
|
| |
NEW YORK, June 6, 2011 /PRNewswire via COMTEX/ --SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced their June 2nd RetailInvestorConferences.com presentation is available for on-demand viewing.
LINK: ...
|
|
Eisai and Janssen Announce the Presentation of DACOGEN® (decitabine) Data at ASCO from a Phase III Study in Patients with Acute Myeloid Leukemia
Jun 6, 2011
|
12.6 KB |
|
| |
CHICAGO, Jun 06, 2011 (BUSINESS WIRE) --Eisai Inc. and Janssen, a Johnson & Johnson Company, both announced the
presentation of data from the DACO-016 trial of DACOGEN® (decitabine) at
the 2011 Annual Meeting of the American Society of Clinical Oncology
(ASCO). The data dem...
|
|
SuperGen, Inc. to Present Live, Online at RetailInvestorConferences.com on June 2nd
May 26, 2011
|
6.6 KB |
|
| |
NEW YORK, May 26, 2011 /PRNewswire via COMTEX/ --SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., president and chief executive officer, will present at RetailInvestorConferences.com.
...
|
|
Astex Therapeutics and Cambridge Crystallographic Data Centre Extend 10-Year Research Collaboration
May 12, 2011
|
12.8 KB |
|
| |
Astex Therapeutics, the fragment-based drug discovery company, and the Cambridge Crystallographic Data Centre (CCDC) today announced a continuation of their research collaboration, which extends a highly successful 10-year partnership.
Astex has a wealth of experience in the field of protein-ligand docking and under the terms of the new...
|
|
Astex Achieves Milestones in GSK Collaboration
May 3, 2011
|
10.9 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009. Total milestone payments received under the collaboration have now reach...
|
|
SuperGen Reports 2011 First Quarter Financial Results
Apr 27, 2011
|
23.2 KB |
|
| |
...
|
|
Astex Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca
Apr 12, 2011
|
11.9 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology, confirms the commencement of a Phase I study for AZD5363, a Protein Kinase B (PKB, also known as Akt) inhibitor. AZD5363 is a clinical candidate selected in January 2010 by AstraZeneca subsequent to its collaborative programme with Astex. The colla...
|
|
SuperGen and Astex Therapeutics Enter Definitive Merger Agreement
Apr 6, 2011
|
15.7 KB |
|
| |
DUBLIN, Calif. & CAMBRIDGE, United Kingdom, Apr 06, 2011 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG), a U.S.-based pharmaceutical company
dedicated to the discovery and development of novel cancer therapies, and
Astex Therapeutics Limited, a privately held, U.K.-based biotechnology
company developing ...
|
|
SuperGen to Webcast 5th Annual Investor & Analyst Day on April 12, 2011
Mar 31, 2011
|
5.7 KB |
|
| |
DUBLIN, Calif., Mar 31, 2011 (BUSINESS WIRE) --SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies,invites all
interested parties to listen and view a live webcast of its 5th Annual
Investor & Analyst Day from 8:30 a.m. to 12:00 p.m....
|
|
SuperGen PIM Kinase Presentations at AACR
Mar 31, 2011
|
5.9 KB |
|
| |
DUBLIN, Calif., Mar 31, 2011 (BUSINESS WIRE) --SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, today announced the
acceptance of three abstracts from the SuperGen PIM kinase inhibitor
program. Poster presentations by SuperGen and collabora...
|
|
Astex To Present Data From Its FGFR Inhibitor Programme at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
Mar 29, 2011
|
13.7 KB |
|
| |
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology, today announced that it is to present new data on Fibroblast Growth Factor Receptor (FGFR) inhibitors from its drug discovery research collaboration with Janssen Pharmaceutica and the Cancer Research UK Drug Discovery Group at the Newcastle Cancer ...
|
|
SuperGen Reports 2010 Fourth Quarter and Year-End Financial Results
Feb 28, 2011
|
22.6 KB |
|
| |
...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter